{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-107725","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2022-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.330717+00:00","generated_at":"2026-06-23T04:13:45.452850+00:00","sec_items":["2.05","5.02","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rigel drops wAIHA sNDA after FDA feedback; cuts 16% workforce, 30 jobs","bullets":["FDA guidance on FORWARD Phase 3 re-analysis leads Rigel to halt sNDA for fostamatinib in wAIHA.","Workforce reduction of 16% (30 positions) primarily in development and admin; completion by Jan 31, 2023.","One-time cash severance charge of ~$1.5M in Q4 2022; expects $7-8M annual savings from 2023.","General counsel Dolly Vance retires effective Oct 11, 2022; remains as employee through Nov 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-107725","json":"https://secwatch.observer/filing/0001104659-22-107725.json","markdown":"https://secwatch.observer/filing/0001104659-22-107725.md","text":"https://secwatch.observer/filing/0001104659-22-107725.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922107725/0001104659-22-107725-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922107725/tm2227881d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:13:45.452850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"773d4323fd","claim":"Dolly A. Vance retired as general counsel at RIGEL PHARMACEUTICALS INC.","evidence_excerpt":"On October 11, 2022, Dolly A. Vance provided notice of her retirement from her position as general counsel, executive vice president, corporate affairs, and corporate secretary of Rigel, effective the date of this current report.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1034842/000110465922107725/0001104659-22-107725-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"general counsel"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}